Clin2
NCT05235074Possibly a fitCompleted

Oncolytic virus treatment for recurrent brain tumors after surgery

Central Nervous System Tumors

Treatments studied

Part of Brain & nervous system, Cancer clinical trials.

This early-phase study tests an oncolytic virus—an anti-cancer virus—given into the brain to treat recurrent brain tumors after surgery. It aims to shrink tumors or slow their growth by directly targeting cancer cells in the brain.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
40 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You’re age 18 or older and can give informed consent
  • Your brain tumor has been confirmed by pathology and is coming back after surgery (Phase II focuses on recurrent glioblastoma)
  • You had part or all of the tumor removed, and an Ommaya reservoir was placed for medicine delivery
  • The trial drug would be injected into the upper part of the brain (supratentorial area), and you’re expected to live at least 3 months
  • Your blood counts and organ tests (liver/kidney) are within required ranges, and clotting tests are acceptable
  • You haven’t had certain cancer treatments or brain radiation very recently, and you don’t have active serious infections or known drug allergies

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03866525Recruiting· Phase 1/Phase 2
Test an oncolytic virus treatment for solid tumors

This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.

Beijing, Beijing Municipality
NCT07472790Not yet recruiting· Phase 1
Oncolytic virus and immunotherapy for recurrent high-grade glioma

This trial tests a new treatment combining an oncolytic virus with a PD-1 inhibitor for people whose high-grade glioma has come back after standard therapy. The virus is injected directly into the tumor through a device placed in the head, and the drug helps your immune system fight the cancer cells.

Beijing, Chaoyang District
NCT06660056Recruiting· Phase 1
GC001 injection for returning or growing high-grade brain tumors

This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.

Beijing, Beijing Municipality
NCT07656116Recruiting· Phase 1
Oncolytic virus therapy for advanced solid tumors

This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.

Langfang, Hebei
NCT07126990Enrolling by invitation· Phase 1/Phase 2
A new virus therapy for untreated high-grade glioma

This trial tests a modified virus that may help treat a type of brain cancer called high-grade glioma. It is for patients who have not yet had any treatment for their tumor.

Beijing, Chaoyang District
NCT05961111Recruiting· Early Phase 1
Oncolytic virus injection for advanced solid tumors

This early-phase trial tests an injection of a virus designed to attack cancer cells in people with advanced solid tumors. It is meant for situations where standard treatments have not worked (or you can’t/won’t take them) and when doctors can directly deliver the treatment to a tumor spot.

Linyi, Shandong

Hear when a new Central Nervous System Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.